Compare CGBD & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CGBD | CSTL |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | United States |
| Employees | 2500 | N/A |
| Industry | Finance: Consumer Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 759.8M | 806.3M |
| IPO Year | N/A | 2019 |
| Metric | CGBD | CSTL |
|---|---|---|
| Price | $11.02 | $25.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $12.92 | ★ $47.17 |
| AVG Volume (30 Days) | ★ 759.2K | 260.4K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | ★ 15.05% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $344,229,000.00 |
| Revenue This Year | $3.74 | $2.42 |
| Revenue Next Year | $1.80 | $12.69 |
| P/E Ratio | $10.36 | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $10.64 | $14.59 |
| 52 Week High | $15.15 | $44.28 |
| Indicator | CGBD | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 46.42 | 40.92 |
| Support Level | $10.64 | $24.89 |
| Resistance Level | $11.44 | $26.19 |
| Average True Range (ATR) | 0.32 | 0.94 |
| MACD | 0.02 | 0.34 |
| Stochastic Oscillator | 48.12 | 65.92 |
Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.